Oncolytic Virus Therapies Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Replimune, Genelux, Candel Therapeutics, DNAtrix, Amgen, etc
Oncolytic Virus Therapy companies working in the market are Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo and others.(Albany, USA) DelveInsight's Oncolytic Virus Therapies Market Insights report includes a comprehensive understanding of current treatment practices, Oncolytic Virus Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
To know more about the Oncolytic Virus Therapies Market report offerings, click here @ [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Oncolytic Virus Therapies market report are:
* In 2021, the total Oncolytic Virus Therapies market size was approximately USD 122 million which is expected to rise during the study period (2020-2034).
* In 2021, the total Oncolytic Virus Therapies target patient pool cases across 7MM were about 632 K which are expected to grow during the study period, i.e., 2020-2034.
* Currently, only two oncolytic virus therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US and Europe in 2015, and DELYTACT (teserpaturev/G47D; Daiichi Sankyo) approved in Japan in 2021.
* Some of the companies working in the Oncolytic Virus Therapies market are Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo and others.
* In November 2023, Genelux announced that the US FDA granted Fast Track designation (FTD) for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum-resistant/refractory ovarian cancer.
Request for Sample Request @ Oncolytic Virus Therapeutic Assessment and Clinical Trials [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Oncolytic Virus Therapies Overview
Oncolytic viruses (OVs), considered an effective anticancer strategy in recent years, are a special type of virus that are naturally or genetically engineered and can replicate preferentially in tumor cells and inhibit tumor growth. Oncolytic Virus Therapies is a treatment using a virus that can replicate itself to kill cancer cells. Many species of viruses exist, but not all can be designed to be oncolytic viruses (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity to be transformed to express tumor-killing factors through genetic engineering methods.
Oncolytic Virus Therapies Epidemiology Segmentation
According to DelveInsight estimates, there were approximately 632K Oncolytic Virus Therapies targeted patient pool in the 7MM in 2021.
Among the 7MM countries, the US had the highest incidence of Oncolytic Virus Therapies in 2021.
The Oncolytic Virus Therapies market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Incident cases of selected cancer types
* Target Patient Pool of Oncolytic Virus Cancer Therapy by Cancer Types
* Total Treated cases by the line of therapies
Download the report to understand which factors are driving Oncolytic Virus Therapies epidemiology trends @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Oncolytic Virus Therapies Pipeline Therapies and Key Companies
* ONCOS-102: Targovax
* RP1 (Vusolimogene Oderparepvec): Replimune
* GL-ONC1: Genelux Corporation
* CAN-2409: Candel Therapeutics
* DNX-2401 (Tasadenoturev): DNAtrix
* PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen
* G207: Treovir
* LOAd703: Lokon Pharma AB
* Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology
* CG0070: CG Oncology
Learn more about the Oncolytic Virus Therapies in clinical trials @ Oncolytic Virus Therapies Market Dynamics and Trends [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Oncolytic Virus Therapies Market Dynamics
Oncolytic viruses have many advantages over other tumor immunotherapies, including high killing efficiency, precise targeting, fewer side effects or drug resistance, and low cost, fueling the oncolytic virus therapies market growth. Furthermore, as certain oncolytic viruses, such as Adeno oncolytic viruses, have demonstrated antitumor memory, they could be used as a cancer vaccine.
In 2015, IMLYGIC (talimogene laherparepvec/T-Vec; Amgen) became the first oncolytic virus approved by the US FDA and later by the European Commission (EC) for the treatment of unresectable melanoma lesions. It harnesses a genetically modified Herpes Simplex Virus Type 1 (HSV-1) to replicate within tumors and stimulate the immune system.
Although these milestones have been achieved, continued progress in oncolytic virotherapy (OV) is evident through clinical trials conducted by major players such as Replimune, DNAtrix, and SillaJen, among others. This signals a promising future for OV therapy in the global fight against various cancers.
Scope of the Oncolytic Cancer Therapies Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Oncolytic Cancer Therapies Companies: Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others
* KeyOncolytic Cancer Therapies in Pipeline: ONCOS-102, RP1 (Vusolimogene Oderparepvec), GL-ONC1, CAN-2409, DNX-2401 (Tasadenoturev), PEXA-VEC (Pexastimogene Devacirepvec; JX-594), G207, LOAd703, Lerapolturev (Formerly Known as PVSRIPO), CG0070, and others
* Therapeutic Assessment: Oncolytic Cancer Therapies current marketed and emerging therapies
* Unmet Needs, KOL's views, Analyst's views, Oncolytic Cancer Therapies Market Access and Reimbursement
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Discover more about emerging oncolytic cancer therapies in development @ Oncolytic Virus Cancer Clinical Trials and FDA Approvals [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Oncolytic Virus Therapies Market Key Insights
2. Oncolytic Virus Therapies Market Report Introduction
3. Oncolytic Virus Therapies Market Overview at a Glance
4. Oncolytic Virus Therapies Market Executive Summary
5. Disease Background and Overview
6. Oncolytic Virus Therapies Treatment and Management
7. Oncolytic Virus Therapies Epidemiology and Patient Population
8. Patient Journey
9. Oncolytic Virus Therapies Emerging Drugs
10. 7MM Oncolytic Virus Therapies Market Analysis
11. Oncolytic Virus Therapies Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Oncolytic Virus Therapies Market Drivers
15. Oncolytic Virus Therapies Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oncolytic-virus-therapies-market-2034-clinical-trials-ema-pdma-fda-approvals-epidemiology-therapies-companies-by-delveinsight-replimune-genelux-candel-therapeutics-dnatrix-amgen-etc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Therapies Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Replimune, Genelux, Candel Therapeutics, DNAtrix, Amgen, etc here
News-ID: 3682402 • Views: …
More Releases from ABNewswire
Circle G Roofing: The Roofing Company That Delivers Exceptional Results Every Ti …
At Circle G Roofing, we take pride in offering high-quality roofing services that ensure your property remains safe, secure, and visually appealing. As a trusted roofing company located in Scottsdale, we have built a reputation for providing reliable, professional roofing solutions tailored to meet the unique needs of every client.
When it comes to protecting your home or business, the roof is one of the most important elements. Not only does…
Winkler Kurtz LLP - Long Island Lawyers Stands Out Among Long Island's Top Perso …
With decades of combined experience, we've built our reputation as one of the leading personal injury firms in Long Island. By providing compassionate support, expert legal guidance, and a proven track record of success, we stand out as the go-to choice when Long Islanders search for "personal injury lawyers near me" or "personal injury lawyers nearby."
At Winkler Kurtz LLP - Long Island Lawyers, we pride ourselves on being a dedicated…
CareKter Design & Remodeling: Setting New Standards in Home Remodeling
Whether it's a complete overhaul of a kitchen, a bathroom transformation, or a full-home redesign,CareKter Design & Remodeling has developed a strong reputation for setting high standards in the world of home remodeling.
The company is known for transforming homes and enhancing spaces with a focus on quality, precision, and style. As a leader among Houston home remodeling contractors, their dedication to excellence is evident in every project. Whether it's a…
Xtreme Fence: The Fencing Company Redefining Quality and Affordability in the In …
When it comes to securing and enhancing properties, the choice of fencing can significantly impact aesthetics, safety, and overall value. In the competitive world of fencing, Xtreme Fence stands out as a pioneering fencing company committed to redefining quality and affordability in the industry. With a focus on customer satisfaction, innovative designs, and a diverse range of materials, Xtreme Fence has established itself as a trusted partner for both residential…
More Releases for Oncolytic
Oncolytic Virus Market: Know Applications Supporting Impressive Growth
A new business intelligence report released by HTF MI with title "Global Oncolytic Virus Market Professional Survey Report 2019" is designed covering micro level of analysis by manufacturers and key business segments. The Global Oncolytic Virus Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
Global Oncolytic Virus Therapy Market & Oncolytic Virus clinical Trials Outlook …
Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the disease.
The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low…
Global Oncolytic Virus Therapy Pipeline Analysis
Though still in nascent stages, Oncolytic viruses have shown immense opportunities and potential to be tapped in the future to improve the treatment of cancer and the lives of the patients. Immunotherapy, the umbrella for Oncolytic viruses would not offer cures, but survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the most important approach to treat…
Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…